Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Top navigation

  • News
    • Press Releases
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • Country List
SEARCH
Home

Main navigation

  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
    • Oncology
    • Dermatology
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  1. Home
  2. Opzelura® (ruxolitinib) cream
  • SEARCH
  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
    • Oncology
    • Dermatology
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • News
    • Press Releases
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • United States

INCYTE AROUND THE WORLD

GLOBAL HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Submitted by incyte_admin on Mon, 02/20/2023 - 04:07

Opzelura® (ruxolitinib) cream

Dermatology and Other IAI

Atopic dermatitis2,5, vitiligo2,5,6

JAK1/JAK2
Approved
26
Dermatology
Footer Logo © 2012-2025 Incyte.
  • LinkedIn Icon
  • Twitter Icon
  • Instagram Icon
  • Facebook Icon
  • Youtube Icon
  • Legal Notice
  • Suppliers
  • Site Map
  • Privacy Policy
  • Cookie Policy
  • Consumer Health Data Privacy Policy